GlobeNewswire: Eyenovia, Inc. Contains the last 10 of 151 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T16:25:40ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/18/2848151/0/en/Eyenovia-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=30688Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update2024-03-18T20:05:00Z<![CDATA[Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery]]>https://www.globenewswire.com/news-release/2024/03/13/2845282/0/en/NovaBay-Pharmaceuticals-and-Eyenovia-to-Co-Promote-Prescription-Ophthalmic-Products-to-U-S-Eyecare-Professionals.html?f=22&fvtc=4&fvtv=30688NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals2024-03-13T11:00:00Z<![CDATA[EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel. Eyenovia will market NovaBay’s prescription Avenova® Antimicrobial Lid & Lash Solution through its Mydcombi and Clobetasol sales representatives strategically located across the U.S.]]>https://www.globenewswire.com/news-release/2024/03/11/2843602/0/en/Eyenovia-to-Report-Fourth-Quarter-2023-Results-and-Provide-Business-Update-on-Monday-March-18th.html?f=22&fvtc=4&fvtv=30688Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th2024-03-11T11:00:00Z<![CDATA[Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT]]>https://www.globenewswire.com/news-release/2024/03/05/2840390/0/en/Eyenovia-Congratulates-Formosa-Pharmaceuticals-on-FDA-Approval-of-Clobetasol-Propionate-Ophthalmic-Suspension-0-05-for-the-Treatment-of-Post-operative-Inflammation-and-Pain-Followi.html?f=22&fvtc=4&fvtv=30688Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery2024-03-05T13:00:00Z<![CDATA[Approval based on nearly 9 out of 10 patients achieving complete absence of post-surgical pain and 6 out of 10 achieving total absence of inflammation within 15 days post-ocular surgery]]>https://www.globenewswire.com/news-release/2024/02/13/2828089/0/en/Eyenovia-Announces-FDA-Approval-of-Redwood-City-as-Commercial-Manufacturing-Facility.html?f=22&fvtc=4&fvtv=30688Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility2024-02-13T12:00:00Z<![CDATA[Redwood City, California to complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi]]>https://www.globenewswire.com/news-release/2024/01/16/2809702/0/en/Eyenovia-Re-Acquires-Development-and-Commercialization-Rights-to-MicroPine-in-the-U-S-and-Canada.html?f=22&fvtc=4&fvtv=30688Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada2024-01-16T12:00:00Z<![CDATA[MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007]]>https://www.globenewswire.com/news-release/2023/11/13/2779451/0/en/Eyenovia-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=30688Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update2023-11-13T21:05:00Z<![CDATA[Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals]]>https://www.globenewswire.com/news-release/2023/11/06/2774018/0/en/Eyenovia-to-Report-Third-Quarter-2023-Results-on-Monday-November-13.html?f=22&fvtc=4&fvtv=30688Eyenovia to Report Third Quarter 2023 Results on Monday, November 132023-11-06T13:00:00Z<![CDATA[Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT]]>https://www.globenewswire.com/news-release/2023/11/02/2772116/0/en/Eyenovia-Announces-FDA-Approval-of-Coastline-International-as-Contract-Manufacturer-to-Initiate-Mydcombi-Commercial-Production.html?f=22&fvtc=4&fvtv=30688Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production2023-11-02T11:00:00Z<![CDATA[Anticipates having product available to ship in January 2024 Anticipates having product available to ship in January 2024]]>https://www.globenewswire.com/news-release/2023/10/30/2769019/0/en/Eyenovia-to-Sponsor-Course-on-Drug-Delivery-Innovation-at-IJCAHPO-s-51st-Annual-Continuing-Education-ACE-Program.html?f=22&fvtc=4&fvtv=30688Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program2023-10-30T11:00:00Z<![CDATA[Course to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis]]>